Overview of Lifeward Ltd.'s Financial Performance
Lifeward Ltd., a recognized leader in innovative solutions for physical rehabilitation and recovery, has announced its financial results for the third quarter of 2024. The company reported significant growth, showcasing a second consecutive quarter with 20 ReWalk systems sold. This success indicates the increasing demand for life-changing technologies that enhance patient recovery, particularly in the U.S. market.
Operational Highlights
During this quarter, Lifeward initiated key actions to streamline its U.S. operations, including the closure of two facilities to integrate the AlterG product line effectively. These strategic moves are expected to save the company approximately $3 million in operating expenses and enhance gross margins. Furthermore, Lifeward has begun selling the AlterG products through its German organization, which is anticipated to foster revenue growth with minimal additional investment.
Recent Product Launches
The successful introduction of the AlterG NEO, which incorporates a new design for a more accessible price point, has quickly become a growth driver. Lifeward received orders for about 40 units since the NEO's release, underscoring its appeal to a broader customer base.
Third Quarter 2024 Financial Results
Lifeward's revenue reached $6.1 million in the third quarter, a 39% increase from $4.4 million in the same quarter the previous year. Sales from its historical product line, including ReWalk exoskeletons, rose dramatically by 173% to $2.5 million. This growth is attributed to improved access for patients under Medicare coverage and enhanced sales efforts in Germany, where revenue from AlterG products grew to $3.6 million.
Gross Margin and Operating Expenses
The gross margin for the quarter stood at 36.2%, a significant increase from 19.6% year-over-year. However, the adjusted gross margin on a non-GAAP basis showed a slight decline due to lower production levels for AlterG systems and rising labor costs. Operating expenses fell to $5.4 million from $8.8 million in the prior year, pointing to effective cost management amidst ongoing development efforts.
Looking Ahead
The company reported a net loss of $3.1 million, or $0.35 per share, which is an improvement compared to the net loss of $7.5 million, or $0.88 per share, recorded a year ago. Additionally, Lifeward's cash position improved, with $10.7 million in unrestricted cash and cash equivalents as of September 30, 2024. The company anticipates full-year revenues in the range of $25 million to $26 million, suggesting a strong finish to the fiscal year.
Management Commentary
Larry Jasinski, the Chief Executive Officer of Lifeward, expressed optimism regarding the growing pipeline of ReWalk cases, which he believes will support future growth. The company is committed to continuing educational efforts surrounding increased patient access under Medicare and private insurance, positioning itself for sustained success in the rehabilitation technology market.
Frequently Asked Questions
What is Lifeward Ltd. known for?
Lifeward Ltd. specializes in life-changing rehabilitation solutions, including advanced technologies like ReWalk exoskeletons and AlterG Anti-Gravity systems.
What were Lifeward's revenue results in Q3 2024?
Lifeward reported a revenue of $6.1 million in the third quarter of 2024, marking a 39% increase compared to the previous year.
How has the launch of AlterG NEO impacted Lifeward's performance?
The launch of the AlterG NEO has generated substantial interest, leading to about 40 units sold, contributing to Lifeward’s overall growth in revenue.
What is Lifeward's future outlook?
Lifeward is revising its full-year revenue expectations to between $25 million and $26 million, supported by a strong fourth-quarter outlook.
Who is the CEO of Lifeward Ltd.?
Larry Jasinski serves as the Chief Executive Officer of Lifeward Ltd.
